Workflow
多项规定促进民营经济发展,核酸业务相关企业债务困境迎来曙光
Hua Xia Shi Bao·2025-05-28 13:14

Core Viewpoint - The IVD industry has experienced explosive growth in the past three years, but many companies face severe cash flow issues due to delayed payments for nucleic acid testing services, leading to a widespread "debt collection" crisis in the sector [2][4][7]. Group 1: Industry Challenges - The nucleic acid testing industry has seen significant revenue increases, but much of this growth is not reflected in actual cash flow, resulting in a "return payment dilemma" [2][4]. - As of the end of 2024, the total amount owed to nucleic acid testing companies exceeded 80 billion yuan, causing a 23% year-on-year decline in R&D investment in the IVD sector and leading to the bankruptcy of 17 small and medium-sized testing institutions [7][8]. - Companies like Beijing Ditai Kexun Biotechnology Co., Ltd. are struggling with substantial accounts receivable, with debts from local health departments remaining unpaid, putting them on the brink of bankruptcy [5][6]. Group 2: Policy Developments - The implementation of the "Private Economy Promotion Law" and the revised "Regulations on Payment of Small and Medium-sized Enterprises" are seen as crucial steps to improve the cash flow situation for IVD companies [3][8]. - The new regulations enhance the rights of companies in debt recovery, allowing them to charge interest on overdue payments and providing legal backing for their claims [8][9]. - The government has acknowledged the long-term debts incurred during the pandemic and is taking steps to address these issues, which is viewed as a positive signal for the IVD industry [8][9]. Group 3: Key Players and Events - Zhang Hezi, founder of Nucleic Huaxi Laboratory, has shifted from being an industry leader to a "debt collector," suing multiple health departments for unpaid nucleic acid testing fees [3][4]. - The company has initiated lawsuits against health authorities in various regions, highlighting the industry's struggle with delayed payments [3][4].